Unconventional properties of zoledronic acid

Published: June 8, 2009
Abstract Views: 177
PDF: 142
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Zoledronic acid (Zol) is the most potent aminobisphosphonate (ABP) currently available to treat bone disease in cancer patients. Zol specifically targets the mevalonate (MEV) pathway of osteclasts precursors and mature osteoclasts. By inhibiting the farnesyl pyrophosphate (FPP) synthase, Zol prevents the generation of FPP and geranylgeranylpyrophosphate (GGPP) that are essential compounds to prenylate proteins like Ras and Rho among others. The accumulation of unprenylated proteins in osteoclast precursors and mature osteclasts prevents their differentiation and activation and ultimately leads to cell death by apoptosis.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Massaia, M., Fiore, F., Castella, B., Pantaleoni, B., Mariani, S., Peola, S., & Hwang, S. (2009). Unconventional properties of zoledronic acid. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.435